Renal
Chronic Kidney Disease
The eGFR racial correction, APOL1 gene variants, and dialysis access disparities.
Last updated April 15, 2026
Who is most affected
- Black adults (roughly 3× higher rates of kidney failure)
- People with APOL1 gene variants (more common in West African ancestry)
- Veterans with diabetes, hypertension, or NSAID-heavy treatment histories
- Patients whose eGFR was reported with the now-discredited race coefficient
Key disparities
- The eGFR race coefficient (used until 2021) systematically delayed diagnosis
- Transplant referral and waitlist times skew against Black patients
- Dialysis access disparities in both quality and proximity of clinics
- APOL1 risk often went unscreened despite known clinical relevance
Placeholder content. Real article forthcoming.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
What the eGFR race coefficient actually did
Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
APOL1 and what your provider should know
Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
What you can ask at your next appointment
- Placeholder action item one.
- Placeholder action item two.
- Placeholder action item three.